Cell
Boehringer boards B-cell depletion bandwagon, paying Cue $12M to line up autoimmune attack
Cues, CUE-501, B-Lymphocytes, Boehringer, Depletion, paying, T-Lymphocyte
Descartes-08: Sustained Efficacy in Myasthenia Gravis as Cartesian Prepares for Phase III Trial
Descartes-08 , Myasthenia Gravis (gMG) , CAR-T therapy , Cartesian Therapeutics , mRNA-based treatment , Phase III AURORA trial , Autoimmune diseases , Clinical trial results
Rocket Pharmaceuticals Expands Leadership with J&J and AstraZeneca Alumni to Strengthen Gene Therapy Commercialization
Rocket Pharmaceuticals, gene therapy, commercial leadership, Sarbani Chaudhuri, Johnson & Johnson, AstraZeneca, commercial launch, gene therapy market, rare diseases, biotechnology, Kresladi, RP-L102.
Cartesian reveals long-term mid-stage data for cell therapy in myasthenia gravis
Autologous Anti-BCMA-CAR-mRNA-transfected CD8+ T-lymphocytes, Myasthenia Gravis, Cell Therapy, Long-term, Cartesian
Vertexs second-generation diabetes cell therapy fails early-stage study
Failed, VX-264, Allogeneic Human Stem Cell-derived Pancreatic Islet Cells VX-880
Nkarta lays off 3rd of staff, including CFO, to fund autoimmune CAR NK program
Nkarta, restructuring, Allogeneic CD19-OX40-CD3zeta-CAR-mbIL-15-expressing Natural Killer Cells NKX019, Cell Therapy
Hillstar Bio Launches with $67M to Develop Precision Immunotherapies for Autoimmune Diseases
Precision immunology, autoimmune diseases, TRBV9+ T cells, axial spondyloarthritis, Series A funding
Roche continues ADC dealmaking spree with $1B biobucks pact with Oxford BioTherapeutics
OBT, therapeutic autologous dendritic cells, Roche (company), Partnership, Oxford BioTherapeutics, Antibody-Drug Conjugates, biobucks, New
Lonza’s Vision for the Future: A Fireside Chat with New CEO Wolfgang Wienand
Lonza, Wolfgang Wienand, CDMO, Pharmaceutical manufacturing, Biologics, Cell and gene therapy, Small molecules, Leadership transition, Industry outlook